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                     ABSTRACT 
 
BACKGROUND: 
Successful periodontal regeneration relies mainly on the re-formation of an epithelial 
seal, deposition of new acellular extrinsic fiber cementum and insertion of 
functionally oriented connective tissue fibers into the root surface, and restoration of 
alveolar bone height. The use of collagen membranes for treatment of periodontal 
defects in regenerative procedures are well known. Collagenase are enzymes 
responsible for degradation of collagen membranes which is detrimental to the 
success of periodontal regeneration. It has been well proven that tetracycline and 
doxycyline have role in inhibition of collagenase enzyme.  
AIM OF THE STUDY: 
To evaluate the effects of varying concentration of tetracycline and doxycycline on 
the rate of degradation of bioresorbable collagen membranes by clostridial 
collagenase when immersed in vitro. 
MATERIALS AND METHODS: 
The rate of collagen membrane degradation were analyzed quantitatively and 
qualitatively using spectrophotometric and microscopic analysis respectively in vitro 
when collagen membranes were incubated in PBS alone (group A), Tetracycline 
hydrochloride at varying concentration with PBS (group B) and Doxycycline hyclate 
at varying concentration with PBS (group C) observed over day 2, 4, 7 and 14 
respectively . Groups were further divided into group I (treated with collagenase) and 
group II (treated without collagenase). Free protein content in the medium of each 
sample were analyzed using spectrophotometric analysis. Each collagen membrane 
sample was observed microscopically to get the overview of general surface 
topography and organization of collagen fibrils after incubation over time. 
RESULTS: 
There was a statistically significant difference in free protein release in the medium 
over the time between groups with and without collagenase and also there was a 
statistically significant difference between group with tetracycline and group without 
any drug and between group with doxycyline and group without any drug and 
between group with tetracycline and doxycycline in chlostridial collagenase.  
 CONCLUSION 
Tetracycline at 50 mg/ml concentration and doxycycline at 20 mg/ml concentration 
are effective in delaying collagen membrane degradation in clostridial collagenase in 
vitro. Also doxycyline 20 mg/ml is more effective in prolonging the collagen 
membrane degradation time when compared to tetracycline 50mg/ml concentration. 
Keywords: Tetracycline hydrochloride, doxycycline hyclate, collagen membrane 
degradation, collagenase  
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                                                   INTRODUCTION 
 
The main goal of periodontal therapy is the predictable regeneration of the lost 
periodontium which allows repopulation of periodontal ligament cells into the wound 
area after periodontal surgery and also prevents the colonization of the 
microorganisms on the exposed root surface of the teeth. Successful periodontal 
regeneration mainly depends upon the re-formation of an epithelial seal, deposition of 
new acellular extrinsic cementum and insertion of functionally oriented connective 
tissue fibers into the root surface, and also the restoration of alveolar bone height
11
.                 
Use of Collagen membranes for the treatment of periodontal defects in regenerative 
procedures are well known. Initially non resorbable barrier membranes such as ePTFE 
were mostly used for the purpose of bone regeneration and guided tissue regeneration 
procedures, but due to their several limitations, they were replaced by bio-resorbable 
membranes which are mainly composed of duramater, polyglycolic acid, polylactic 
acid, polyurethane and collagen. Bio absorbable membranes helps in maturation of 
newly formed tissues only if its structural integrity is preserved for sufficient period 
of time. Various materials have been used to delay the collagen membrane 
degradation. 
Matrix metalloproteinases, zinc dependent enzymes are responsible for the 
degradation of collagen membranes which is detrimental to the success of periodontal 
regeneration. They are considered to be key initiators of collagen degradation, thus 
they are contributing to bone resorption in inflammatory diseases. Alteration in 
collagen degradation can be achieved by either cross linking which increases the 
___________________________________________________________________Introduction 
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structural integrity or by delaying the degradation process of collagen. MMP 
inhibitors can modify the collagen degradation process. 
Tetracycline have long been used in treatment of periodontal diseases due to their 
antimicrobial properties and their intrinsic anti-inflammatory activity. Tetracycline 
has inhibitory effects on matrix metalloproteinases which provides a therapeutic 
advantage in Periodontal regeneration
22
. Doxycycline, a semisynthetic tetracycline 
has been effective in reducing excessive collagenase activity in the gingival crevicular 
fluid of chronic periodontitis patients
25
.  
Hence this study has been undertaken to evaluate the effects of varying concentration 
of tetracycline hydrochloride and doxycycline hyclate on the rate of degradation of 
bioresorbable collagen membranes by clostridial collagenase when immersed in vitro. 
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                                                AIM AND OBJECTIVES 
 
Aim: 
To evaluate the effects of varying concentration of tetracycline and doxycycline on 
the rate of degradation of bioresorbable collagen membranes by clostridial 
collagenase when immersed in vitro. 
Objectives: 
1. To evaluate and compare the effects of varying concentration of tetracycline 
with and without collagenase on the amount of protein released in the medium 
in vitro 
2. To evaluate and compare the effects of varying concentration of doxycycline 
with and without collagenase on the amount of protein released in the medium 
in vitro 
3. To visualize microscopically the degradation of collagen membrane in varying 
concentration of tetracycline, doxycycline and in absence of any drug 
respectively.  
4. To compare the effects of tetracycline and doxycyline on the rate of 
degradation of collagen membrane in vitro.  
              ______________________________________________________________Review of Literature 
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                                                 REVIEW OF LITERATURE 
          
        COLLAGEN MEMBRANE DEGRADATION AND ENZYME INVOLVED 
                                               
The use of Collagen membranes for the treatment of Periodontal defects in 
regenerative procedures such as Guided tissue regeneration is widespread. 
Initially non resorbable barrier membranes were used but later on Bio 
resorbable membranes were introduced to overcome the limitations of non 
resorbable membranes. 
 
As compared with non-resorbable membranes, resorbable collagen membranes 
show a lower incidence of spontaneous exposure to the oral environment, and 
also unlike non-resorbable membranes, infection is not associated with soft 
tissue healing following exposure of resorbable collagen membranes. 
(Friedmann et al 2002)
13
. Collagenase enzyme is known to be responsible for 
the degradation of collagen membranes which is detrimental to the success of 
regenerative procedures.  
Two possible mechanisms of collagenolysis (Weiss JB 1976)
82 
in vivo: 
a) Collagenase, an enzyme is capable of initiating collagen degradation by 
cleaving a single peptide bond on the helical portion of the three subunit 
chains of the native substrate and continuing the further breakdown of the 
              ______________________________________________________________Review of Literature 
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reaction products unaided by other enzymes but helped by their 
denaturation at physiologic temperature 
 
b)  the multiple enzyme mechanism suggests that several enzymatic steps are 
necessary to degrade native insoluble collagen, starting with 
depolymerization (catalyzed by nonspecific proteolytic enzymes), 
followed by specific cleavage by  the collagenases, and continued by 
digestion of denatured reaction products, first by specific endopeptidases 
and exopeptidases, then by peptidases of low specificity, and finally by 
nonspecific exopeptidases. 
The rate-limiting factor in physiologic collagen degradation are variations 
in enzyme activity and concentration and changes in substrate 
susceptibility.   
             In 1953, MacLennan et al
43
, showed the beginning of study on 
collagenases with recognition of the involvement of the proteolytic clostridia 
in tissue putrefaction and the subsequent isolation of clostridium histolyticum, 
an extracellular enzyme that was able to digest tendons.           
             Gibbons, R. J., and J. B. MacDonald
16
 in 1961 reported first 
organism   possessing collagenolytic activity in the human oral cavity. 
             In 1962, Gross and Lapie're
29 
described an in vitro method where 
they demonstrated the existence of endogenous specific collagenase in animal 
tissues. They also reasoned that an enzyme such as collagenase was a 
potentially dangerous substance, so that a regulation of synthesis, activity, and 
diffusion was essential  
              ______________________________________________________________Review of Literature 
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             Rippon, J. W
62
 in  1968, reported in a case of human mycetoma, that 
isolated strain of Actinomadura (Streptomyces) madurae  was shown to 
produce a collagenase with activity against native collagen.  Kivirikko KI et 
al
38 
in 1970 established that a small but a significant fraction of total body 
collagen is rapidly synthesized and degraded throughout life, and this fraction 
is quantitatively different in various tissues, and that abnormal collagen 
degradation, either by excess or deficiency, might play a role in some human 
diseases. 
             Fullmer HM 1971, Page RC, Schroeder HE
14
 in 1973, suggested 
that increase in collagenase production has been found in situations in which 
massive collagen degradation is clearly documented, e.g. periodontal disease. 
             Ohlsson K, Olsson I
55
 in 1973, reported about specificity of 
collagenases for collagen, the enzymes seem to attack few or no other 
proteins; the exception to this is leukocyte collagenase, which in highly 
purified form will also degrade fibrinogen and proteoglvcans. Then in 1973, 
Harris ED Jr. Krane SM
32
, also found that kinetics of collagenolytic attack 
depends upon the degree of aggregation and cross linking of the substrate. 
Under identical conditions of incubation, the soluble collagen molecules are 
more susceptible than reconstituted fibrils and the susceptibility decreases 
with the number of cross-links in the substrate. 
              In 1974, Robertson et al
63
, suggested that bacterial proteinases may 
be capable of activating latent mammalian collagenases, thus they contribute 
to the degradation of collagen indirectly. Montfort I, Perez-Tamayo R
48 
in 
1975, surveyed many different tissues of the normal rat and then detected 
collagenase bound to the three major histologic types of collagen, i.e. collagen 
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bundles, reticulum fibers, and basement membranes and finally stated that 
collagenases are present in the extracellular structures of normal animals. 
             Weiss JB
82
 in 1976 established that pure preparations of almost all 
types of animal collagenases cleave the native soluble collagen or 
reconstituted collagen fibrils at a single peptide bond, when incubation is 
carried out at physiologic pH and ionic strength and at temperatures which is 
below the denaturation point of the reaction products (30 C).                                                                                                          
             Steven FS
75
 in 1976 then found in his study that when a 0.02% 
solution of human skin collagenase was incubated with approximately 2 to 3 
mg of whole fresh human skin dermis at 37 C for 14 hours, approximately 
25% of the hydroxyproline in the tissue is released into the medium, when 
compared with no liberation of hydroxyproline in the absence of the enzyme. 
             In 1977, Stricklin GP et al
76
  stated that collagenases have been 
claimed to occur in animal tissues and fluids in at least in three molecular 
forms: a) latent enzyme, b) free enzyme, and c) collagen-bound enzyme.; 
Stricklin et al also claim that these molecular forms of collagenase are true 
zymogens or precursors of the active form of the enzyme, which are 
synthesized and secreted by different cells as such. Such proenzymes would 
require their activation by specific mechanisms, which may be partial 
proteolysis by other enzymes, so-called auto-activation 
             Horwitz AL. Hance AJ. Crystal RG
34
 in 1977, suggested that the 
influence of the genetic type of collagen on its susceptibility to specific 
collagenase attack is the difference in the rate of degradation of Types I and III 
by polymorphonuclear leukocyte collagenase 
              ______________________________________________________________Review of Literature 
8 
 
             In 1979, Smith, L. D. S.
69
 found that clostridial collagenases were the 
first enzymes of this group to be identified and characterized and have become 
the benchmark against which newly discovered collagenolytic enzymes are 
later compared. Clostridium perfringens is the most common pathogen of 
clostridial myonecrosis (gas gangrene) and has also been identified as a major 
etiological agent in other necrotizing diseases, including enteritis necroticans, 
necrotizing enteropathy, necrotizing pneumonia, and gangrenous cholecystitis. 
The organism has been shown to produce a large number of tissue-destroying 
enzymes including  collagenase which is known as kappa toxin. 
             Then in 1984 Bond, M. D., and E. Van Wart
7
, reported a second 
clostridial species associated with myonecrosis, C. histolyticum, which has 
capability to produce upto six electrophoretically different collagenases 
             Sorsa T et al
70 
 in 1988, suggested that PMNs are the cells that 
provide the major source of collagenase that mediates tissue breakdown during 
inflammatory periodontal disease, whereas fibroblasts contribute the 
collagenase required for connective tissue remodeling in normal gingiva. 
             Jin, K.et al
36
 in 1989, suggested that Porphyromonas gingivalis is the 
only black-pigmented anaerobic rod that produces significant collagenase 
activity under the appropriate assay conditions. Harrington, D. J., and  R. B. 
Russell
31
 in 1994, suggested that these enzymes may contribute to the 
breakdown of the collagen component of both dentine and cementum in the 
pathogenesis of dentinal and root surface caries.                                                
              Lekovic V et al
42
 in 1997, stated that there is no need for a second 
surgical intervention for removal of the bio-absorbable membrane along which 
they present improved soft tissue healing, the incorporation of the collagen 
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membranes by the host tissues and rapid resorption if exposed eliminate open 
microstructures prone to bacterial contamination 
              Lee SJ et al
41
 in 2001, stated that barrier membranes must satisfy 
space maintenance, tissue integration, cell-occlusiveness, and biocompatibility 
criteria. Among these properties, optimal space maintenance is the most 
important property to ensure the success of the periodontal treatment. Space 
maintenance by the barrier membrane is necessary to withstand the forces 
exerted by the overlying soft tissue ﬂaps, to prevent the collapse of the soft 
tissue, and also to maintain wound space 
             In 2003, Michael N. Sela et al
47
 examined the role of periodontal 
bacteria and their enzymes in the degradation of commercially used collagen 
membranes. Degradation of two collagen membranes (Biomend
 
and Bio-
Guide) 
 
labelled by fluorescein isothiocyanate was examined by measuring 
soluble fluorescence. Porphyromonas gingivalis, Treponema 
denticola and Actinobacillus actinomycetemcomitans and their enzymes were 
evaluated. Collagenase from Clostridium histolyticum was used as a positive 
control. These results suggested that proteolytic bacterial enzymes may take 
part in the degradation of barrier membranes used for the guided tissue 
regeneration. 
             Moses et al
49
 in 2005, found in his comparative study between the 
prematurely exposed non-resorbable membranes (ePTFE), non-cross-linked 
collagen membranes (BioGide) and cross-linked collagen membranes (Ossix), 
the latter were claimed to be superior, and capable of supporting healing.  
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             Schwarz et al
65
 in 2006, proposed that the vascularization process 
may also be contributed to membrane degradation since the monocytes 
penetrating through the blood vessel wall may differentiate into macrophages 
             Ofer Moses et al
53
 in 2010, found in his study that immersion of 
collagen membranes in TTC solution prior to their implantation and systemic 
administration of TTC significantly decreased the membranes' degradation in 
vivo 
 
 
ROLE OF MATRIX-METALLOPROTEINASES IN PERIODONTAL 
INFLAMMATION 
                                    
             Matrix metalloproteinases are the zinc dependent enzymes produced 
both by infiltrating and resident cells of the periodontium, play a role in 
(i) physiological (such as tooth eruption) and 
(ii)  pathological (such as periodontitis) events.  
An imbalance between activated matrix metalloproteinases and their 
host-derived endogenous inhibitors leads to the pathological 
breakdown of the extracellular matrix during periodontitis and other 
diseases (Birkedal-Hansen H 1993)
5 
             In 1962, Gross J, Lapiere C
29
 reported first the prototype of host-
derived, connective tissue destructive matrix metalloproteinases, namely 
interstitial collagenase (matrix metalloproteinase-18 or Xenopus collagenase-
483). They also found an active enzyme in the culture media of tissue 
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fragments of the tail fin skin that degraded the triple helix of native type I 
collagen. 
             Golub L et al
18
 in 1985  reported the detection of the elevated levels 
of active rather than latent collagenase in the fluid of the periodontal pocket 
and in the extracts of the adjacent inflamed gingival tissue. 
             Sorsa T et al
70
 in 1988 stated that the influence on the source of 
collagenolytic activity may arise from the level of extracellular activation, as 
evidence exists that polymorphonuclear leukocyte–type and fibroblast-type 
matrix metalloproteinases may respond differently, in the extracellular matrix, 
to factors that activate their respective zymogens   
             Birkedal-Hansen H
5
 1993, found that during inflammatory 
destruction, the most important component of lost periodontium is the 
collagen type I that is found in the periodontal ligament and the alveolar bone 
organic matrix. Four distinct pathways may be involved with this destruction: 
(i) Plasminogen-dependent, (ii) phagocytic, (iii) osteoclastic, and (iv) MMP 
pathway. They also reported that Gingival fibroblasts, keratinocytes, resident 
macrophages and polymorphonuclear leukocytes (PMN) are capable of 
expressing MMP-1, MMP-2, MMP-3, MMP-8, MMP-9. Later on in 1993 
again, they reported that matrix metalloproteinases are expressed in response 
to specific stimuli by resident connective tissue cells as well as the major 
inflammatory cell types that invade the tissue during remodeling events in 
vivo                                  
                Makela M et al
44
 in 1994 reported that MMPs are present in both 
the active and latent forms in chronically inflamed gingival tissues and 
gingival crevicular fluid. Active collagenase and gelatinase were found in the 
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crevicular gingival fluid of patients with periodontitis in much larger amounts 
than in control subjects 
                Golub L et al
23 
 in 1995 reported that Inflammatory cells such as 
neutrophils and macrophages produce matrix metalloproteinases, with 
neutrophils being the major source of collagenase and gelatinase in 
inflammatory diseases such as periodontitis. They also reported that matrix 
metalloproteinase-8 was found to be the main interstitial collagenase in 
gingival extracts and gingival crevicular fluid 
                Van der Zee E
79
 in 1996 stated that MMPs are the major players in 
collagen breakdown during periodontal tissue destruction                                                                                          
                Ramamurthy MS et al
61
 in 1998 reported that the topical 
application of CMT-2, an inhibitor of MMPs activity, can enhance wound 
healing in diabetic rats. They also reported that the treatment with non-
antimicrobial tetracycline prevents not only the destruction of periodontium by 
MMPs, but also avoids the exposure of roots to host tissue.                                              
                Opdenakker G et al
56
 1998, suggested that during an inflammatory 
response, leukocyte trafficking through tissue barriers, including basement 
membranes, is only possible if these cells are equipped with enzymes that can 
remodel the extracellular matrix.                                             
                Souza AP et al
73
 2000, demonstrated that divalent metal salts, as 
Zn, Cu, Hg and Sn, are capable to inhibit the activity of MMP-2 and MMP-9 
at low concentration. Gerlach RF et al
15
 2000, stated that lead, cadmium and 
zinc inhibit the activity of enamel matrix proteinases in vitro.  Kleifeld O et 
al
39
 2000, reported that when cells produce MMPs, most of the enzymes are 
secreted in a latent pro-form and removal of the pro-peptide (about 10 kDa) 
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from the active site, for example, by proteolysis, leads to activation of the 
enzymes  
                Uchida M et al
78
 2001, demonstrated that MMP3, MMP9, and 
MMP13 mRNA levels are increased when osteoblast cultures are stimulated 
by resorptive factors such as cytokines interleukin (IL)-1b and tumor necrosis 
factor (TNF)-α, parathyroid hormone, and prostaglandin E 2 . 
                Visse R et al
80
 2003 suggested that in addition to regulation by 
activation processes and gene expression, the activities of MMPs are also 
controlled by the four natural tissue inhibitors of metalloproteinases (TIMPs).  
                Bildt et al
4
. in 2008 reported that the total MMP-9 levels and its 
active form have been  demonstrated to significantly increase with periodontal 
inflammation in comparison to controls, composed of gingivitis and healthy 
subjects, and to drop along with inflammation  after periodontal therapy 
                Kessenbrock et al
37
 2010 stated that MMPs share a basic structure 
composed of three domains, namely the pro-peptide, catalytic and the 
hemopexin-like domain; the latter is linked to the catalytic domain via a 
flexible hinge region. The proteolytic activity of MMPs is subjected to a 
complex regulation that involves three major steps 1) gene expression, 2) 
conversion of zymogen to active enzyme and 3) specific inhibitors.  
                Sorsa et al
72
 2011, Buduneli et al
8
 2011found that the patho-
physiological significance of increased MMP expression in periodontitis will 
rely ultimately on the presence of endogenous inhibitors and activating 
enzymes that will determine overall MMP activity 
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 INHIBITION OF MATRIXMETTALOPROTEINASES BY 
TETRACYCLINE  
 
Periodontal pathogenic bacteria such as Treponema denticola and P. 
gingivalis, were 
shown to adhere to different barrier membranes in vitro, and cause rapid 
degradation 
of collagen membranes. Since early degradation of collagen membranes is 
detrimental to the success of regenerative procedures, various materials 
include tetracycline impregnation, doxycycline, chlorhexidine dihydrochloride 
which delayed collagen membrane degradation, has inhibitory effects on 
bacterial adherence and early degradation is of great importance in 
periodontics as membrane loaded with these materials might have enhanced 
regenerative efficacy.  
                   In 1954, Stephens CR et al
74
 reported the first chemically 
purified tetracycline, chlortetracycline. Tetracyclines were discovered in 1948 
as natural fermentation products of a soil bacterium, Streptomyces 
aureofaciens. 
                   Gordon et al
25
 1981, stated that tetracyclines have a unique 
ability, antibiotics to concentrate in the GCF of the periodontal pocket at 
levels 5-10 times greater than those found in serum. 
                   Slots J
68
 1983, reported that tetracycline has been shown to be 
considerable benefit in the treatment of aggressive periodontitis (AP) in which 
the prime pathogen, Aggregatibacter actinomycetemcomitans, is very 
susceptible to the antibiotic 
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                   Goodson JM et al
24
 1983, reported that tetracyclines are usually 
given orally, although topical application have been used in periodontal 
treatment regimen. 
                   Golub et al
17
 1984, reported that non-anti-microbial properties of 
chemically modified tetracyclines (CMTs) show great promise in their 
therapeutic value. These properties consist of the inhibition of mammalian 
collagenase. Then in 1985, they found that tetracycline, doxycycline, and 
minocycline can all suppress the activity of the tissue enzyme collagenase as 
determined by its presence in crevicular fluid. In 1990, they stated that  the 
ability of pharmacologic concentrations of tetracyclines to inhibit PMN but 
not fibroblast collagenase may be therapeutically important; therapy with 
these drugs would be expected to reduce pathologically elevated 
collagenolytic activity (e.g., during inflammation), but not the collagen 
turnover required to maintain normal tissue integrity. 
                   Chopra  et al
10
  1985 stated that tetracyclines are bacteriostatic 
inhibitors of protein synthesis. They accumulate intracellularly by way of 
energy dependent transport systems present in bacterial membrane                                                
                   O'Connor BC et al 1990
52
, reported that strict anaerobic bacteria 
are susceptible to tetracyclines, although some black-pigmented bacteroides 
have been reported to be minocycline-resistant   
                   Golub et al
19
 1991, stated that in addition to interstitial 
collagenase, other matrix metalloproteinases (MMPs) inhibited by tetracycline 
include type IV collagenase/gelatinase, stromelysin, and macrophage elastase. 
The anti-collagenolytic activity of tetracycline is independent of its 
antibacterial property                      
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                    Parashis and Mitsis
57
 in 1992 evaluated the potential effect of 
tetracycline root preparation on regeneration in Class II furcation defects 
found no additional improvement in the sites treated with guided tissue 
regeneration in conjunction with tetracycline as compared with barrier 
membrane placement alone.                   
                  Grevstad HJ et al
27
 1993 reported that tetracycline besides having 
antimicrobial activity are also able to inhibit the activity of interstitial 
collagenases present in variety of cells such as neutrophils and macrophages. 
Ingman T et al
35
 1993, reported that Human PMNs are the source of the 
crevicular fluid collagenase that is most susceptible to tetracyclines, while that 
from fibroblasts, which is the source of collagenase in LJP, is relatively 
resistant  
                   Golub et al
21
 1994, found that main therapeutic mechanism of 
action of tetracycline is a direct block of already-active collagenase in the 
periodontal pocket or inhibition of the activation of latent forms of 
collagenase. They also reported that tetracyclines have been shown to block 
the proenzyme conversion to an active state, to block the active enzyme, and 
to inhibit reactive oxygen species that may be involved in activation of MMPs 
and also found in his study that inhibition of MMPs by tetracyclines is 
unrelated to the antibacterial action.                    
                   Shapira LL et al
66
 1996, reported that tetracyclines, besides 
acting as antibiotics, may also affect inflammation, immunomodulation, cell 
proliferation, and angiogenesis.                   
                   Chung et al
12
 1997, stated that inflammatory cytokines including 
TNF-alpha, IL-1 beta, and IL-6 are markedly down-regulated in patients 
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during treatment with tetracyclines. This phenomenon also reduces the amount 
of MMP’s present in inflamed tissues, contributing to a reduction of the 
collagenolytic activity  
                 Ofer Moses et al
54
 in 2001
 
proved that collagen membranes 
immersed in 50 mg/ml tetracycline hydrochloride solution exhibited the 
longest degradation time, both in clostridial collagenase and human bone 
lineage cell assays In vitro. 
                Acharya MR et al
1
 in 2004, reported that tetracyclines are 
antibiotics that also inhibit the breakdown of connective tissue. Chemically 
modified tetracyclines (CMTs) without antibiotic activities have several 
potential advantages over conventional tetracyclines due to the absence of 
gastrointestinal side effects or toxicity and higher plasma concentrations can 
be reached for prolonged periods of time. 
               Sang-Bae Lee et al
64
 2008, found in his study that the collagen 
membrane has an antibacterial performance by the incorporation of 
tetracycline into a biodegradable polymer. In order to control the release rate 
of tetracycline, concentration of three polymers that have different molecular 
weight was changed and then it was coated on the collagen membrane. The 
antibacterial effect of PLA and PLGA was decreased when concentration of 
polymer was increased. Such result supports the result of drug release. Initial 
drug release was largely shown after 1 day. It seemed to largely increase 
antibacterial by releasing a large amount of drug when concentration of 
polymer was decreased.  
                   Ofer Moses et al
53
 2010, found in his study that immersion of 
collagen membranes in TTC solution prior to their implantation and systemic 
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administration of TTC significantly decreased the membranes' degradation in 
vivo        
             
 INHIBITION OF MATRIXMETTALOPROTEINASES BY 
DOXYCYCLINE  
 
              Walker CB et al
81
 1985, found that locally used doxycycline has 
been shown to concentrate in crevicular fluid, successfully eliminated 
Actinobacillus  actinomycetemcomitans and demonstrated a wide spectrum of 
activity against other suspected periodontal pathogens 
               In 1986, Mandell RL et al
46
 suggested that a combination of 
surgical debridement plus systemic doxycycline for 14 days was effective in 
eliminating or suppressing A.a.comitans from periodontal pockets, but this 
emphasized the possibility of re-infection from other oral sites or incomplete 
elimination. 
               Pascale D et al
58
 1986, found that doxycycline achieved gingival 
fluid levels of 4 to 10 Vg/mol after the administration of 100 mg every 12 
hours for the first day, followed by 100 mg/day for 14 days. 
               Golub et al
20
 1990, reported that patients with adult periodontitis 
were administered either 30 mg doxycycline BID or a placebo for two weeks. 
Patients received oral hygiene instructions, scaling and root planing, and 
surgery which included the removal of gingiva and the collection of Gingival 
Crevicular fluid. A reduction in extracellular collagenase activity by 
approximately 60-80% was seen in the crevicular fluid of periodontal pockets 
and in the gingival tissue 
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                Kulkarni GV et al
40
 1991 reported that in patients identified as 
having refractory periodontitis, based on recent attachment loss > 2 mm and 
the presence of periodontal abscesses despite the regular periodontal 
supportive treatment, administration of doxycycline for three weeks showed 
no further disease activity for up to seven months. Most pathogens were 
reduced except for A.a.comitans. This long-term effect may be due to a 
combination of doxycycline's antibacterial and anti-collagenolytic action.    
              Grevstad HJ & Boe OE
28
 1995 found that doxycycline, the most 
potent and cost effective tetracycline commercially available, has been shown 
to reduce the collagenase production by osteoblasts and osteoclasts and also to 
delay osteoclasts recruitment following dental surgery. 
               Ashley RA et al
2
 1999 found that the therapeutic action of 
doxycycline witnessed is primarily due to the modulation of the host response 
because the low-dose formulations of these drugs have lost their antimicrobial 
activity. Thomas J, Walker C & Bradshaw M
77
  2000suggested that low 
dose doxycycline decreases attachment loss and excessive collagenase activity 
in Crevicular fluid of periodontitis patients 
              Sorsa T et al
71
 2006 reported that the tetracycline analogue, 
doxycycline hyclate, available for use specifically in periodontal disease, is the 
only collagenase inhibitor approved by the United States Food and Drug 
Administration (FDA) for any human disease. 
            Prashant S. Dalvi et al
59
 2011 found the beneficial effect of anti-
inflammatory and MMP-inhibiting property of short-term doxycycline in lung 
function parameters and systemic inflammatory marker, CRP in patients of 
stable COPD. 
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                                   MATERIALS AND METHODS 
 
3.1 Materials: 
Preparation of Collagen membrane  
Collagen bio-absorbable membrane (periocol)  
Digital weighing machine  
Sterile cutting instrument 
Tweezer 
Preparation of Collagenase enzyme and Enzyme Buffer 
Collagenase enzyme (Sigma Aldrich laboratories) 
Collagenase enzyme buffer (500 ml) 
- 50 mM Tricine (weight 4.47 g) 
- 10 mM Cacl2 (weight 0.55g) 
- 400 Mm NaCl (weight 11.6 g) 
- pH = 7.5  
Digital pH meter  
Preparation of Tetracycline Hcl and Doxycycline solution 
Pure Tetracycline hydrochloride (500 mg capsules) (Sigma Aldrich laboratories) 
Pure Doxycycline hyclate (100 mg capsules) (Sigma Aldrich laboratories) 
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Phosphate buffer saline 
Test tubes 
Test tube holder 
Distilled water 
Glass beaker 
Magnetic stirrer  
Digital pH meter  
Normal Saline 
 
Spectrophotometric analysis 
Spectrophotometer 
Bradford reagent 
Spectrophotometer test tube (cuvettes) 
 
Optical microscopic Examination 
Optical Light microscope 
Microscope slides 
Cover slips 
 
___________________________________________________________________Materials & methods 
22 
 
3.2 Methods: 
3.2.1 Preparation of Collagen membrane  
Collagen bio-resorbable membranes were cut into rectangular sheets of 5 Х 10 mm 
(average measured weight of 5 ± 1 mg).  
3.2.2 Preparation of Collagenase 
 
3.2.2.1  Preparation of Collagenase enzyme buffer (500 ml) 
Collagenase enzyme buffer were prepared from 50 mM Tricine (weight 4.47 g), 10 
mM Cacl2 (weight 0.55g), 400 Mm NaCl (weight 11.6 g) at pH = 7.5  
3.2.2.2 Preparation of Clostridial Collagenase (15 collagen digestion units) 
1 mg of collagenase contains 800 collagen digestion units 
3 mg of collagenase mixed in 1 ml collagenase enzyme buffer contains 2400 collagen 
digestion units  
1 µl of collagenase + collagenase buffer contains 2.4 collagen digestion units 
6.25 µl collagenase + collagenase buffer contains 15 collagen digestion units 
3.2.3 Preparation of Phosphate buffer solution 
Phosphate buffer solution were prepared with 0.1 M concentration at pH= 7.4. 
3.2.4 Incorporation of drugs to collagen membrane 
3.2.4.1 Tetracycline hydrochloride  
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Four concentration of TTC-Hcl was prepared i.e. 5mg/ml, 20mg/ml, 50mg/ml, 
100mg/ml 
5mg/ml – 50mg TTC- Hcl powder in 10 ml saline 
20 mg/ml – 200mg TTC- Hcl powder in 10 ml saline 
50 mg/ml – 500mg TTC- Hcl powder in 10 ml saline 
100 mg/ml – 1000mg TTC- Hcl powder in 10 ml saline 
3.2.4.2 Doxycycline hyclate  
Four concentration of Doxycycline hyclate was prepared i.e. 5mg/ml, 20mg/ml, 50 
mg/ml, 100 mg/ml 
5mg/ml – 50mg Doxycycline hyclate powder in 10 ml saline 
20 mg/ml – 200mg Doxycycline hyclate powder in 10 ml saline 
50 mg/ml – 500mg Doxycycline hyclate powder in 10 ml saline 
100 mg/ml – 1000mg Doxycycline hyclate powder in 10 ml saline 
 
Sample Groups 
Group A (control) – Phosphate buffered solution alone  
Group B (Test 1) – Tetracycline hydrochloride in Phosphate buffered solution 
Group C (Test 2) – Doxycycline hyclate in Phosphate buffered solution 
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All the three groups were further divided into Group I & Group II 
Group I – treated with collagenase  
Group II – treated without collagenase  
 
3.2.5 Incubation of Collagen membrane in PBS & Drugs 
Incubation of Collagen membrane sheets were done in group A (control group - PBS 
alone) at 4
0
C temperature for 24 hours  
Incubation of Collagen membrane sheets were also done in four varying 
concentrations (5mg/ml, 20 mg/ml, 50 mg/ml, 100 mg/ml) of group B (Tetracycline 
in PBS) and group C (Doxycycline in PBS) respectively at 4
0
C temperature for 24 
hours. 
 
3.2.6 Incubation of Collagen membrane in Collagenase 
After 24 hours of incubation of collagen membrane in group A as well as group B and 
group C, 8the collagen membrane sheets were then rinsed with distilled water 
followed by incubation of collagen membrane sheets in Bacterial (Clostridial) 
Collagenase with collagenase enzyme buffer containing 15 collagen digestion units. 
 
3.2.7 Spectrophotometric analysis 
 A series of protein standards using BSA diluted with 0.15 M NaCl to final 
concentrations of 0 (blank = NaCl only), 250, 500, 750 and 1500 µg BSA/Ml were 
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prepared. Also serial dilutions of the control group, group A and group B samples to 
be measured were prepared. 
Then, 100 µL of each of the above samples were added to a separate test tube 
followed by addition of 5.0 mL of Coomassie Blue to each tube and mix by vortex, or 
inversion. 
 The spectrophotometer to a wavelength of 595 nm were adjusted, and blank using the 
tube which contains 0 BSA. 
After 5 minutes, each of the standards and each of the samples at 595 nm wavelength 
were read. 
 The absorbance of the standards vs. their concentration were plotted. The extinction 
coefficient were computed and the concentrations of the unknown samples were 
calculated on day 2, 4, 7, 14. The data collected were statistically analyzed. 
 
3.2.8 Optical Light Microscopic Examination 
 Collagen membrane sheet from each solution were observed on 2, 4, 7 and 14 days. 
Samples were placed on a microscope slide and then covered with a coverslip and 
viewed under the microscope objective at magnification values of 40 X & 100 X.  
Each collagen membrane samples were observed to get the overview of general 
surface topography and organization of collagen fibrils after incubation in group A I, 
B I, CI over the day 2, 4, 7 and 14.  
In order to avoid bias, the assessment of the morphological characteristics were done 
by a single investigator who was unaware of the origin of the specimen.  
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OBSERVE UNDER MICROSCOPE                                                                                                                               
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                                            STATISTICAL ANALYSIS 
 
The statistical package SPSS V 17 (Stastistical Package for social Science, version 
17) was used for statistical analysis.  
Student’s Independent t-test 
The independent t-test was used to compare the statistical significance of a 
possible difference between the means of two groups on some independent variable 
and the two groups were independent of one another. Here, independent t-test was 
used to compare the means values of free protein in medium between groups with and 
without collagenase. 
The formula for the independent t-test was 
,  
where 
is the mean for group 1, 
is the mean for group 2, 
is the sum of squares for group 1, 
is the sum of squares for group 2, 
n1 is the number of samples in group 1, and 
n2 is the number of samples in group 2. 
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The t-value found was the difference between the two means divided by their 
sum of squares and taking the degrees of freedom into consideration. 
 
and 
 
The degrees of freedom for the independent t-test used was: 
 
One-way Analysis of Variance: 
 The ANOVA is used with one categorical independent variable and one 
continuous variable. The independent variable can consist of any number of groups 
(levels). 
The formula for one way Analysis of Variance is 
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SSwithin = SStotal - SSamong 
dfamong = r-1 dfwithin = N-r 
 
 
 
 
 
x = individual observation 
r = number of groups 
N = total number of observations (all groups) 
n = number of observations in group  
 
Tukey's post-hoc test: 
 To answer the pair comparisons, we run a series of Tukey's post-hoc tests, 
which are like a series of t-tests. 
 
  
   
M = treatment/group mean 
n = number per treatment/group 
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 The P value or calculated probability is the estimated probability of rejecting 
the null hypothesis (H0) of a study question when that hypothesis is true. The smaller 
the p-value, the more significant the result is said to be. All P-values are two tailed, 
and confidence intervals were calculated at the 95% level. Differences between the 
two populations were considered significant when p < 0.05. 
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                                                 RESULTS 
In this study, 108 bioabsorbable collagen membrane samples were obtained and the 
samples were divided into three groups where each group was treated with 6 samples 
individually:  
Group A (control group) was treated with Phosphate Buffer solution without any drug  
Group B was treated with Tetracycline Hcl dissolved in Phosphate buffer solution 
each at 4 different concentrations of 5 mg/ml, 20 mg/ml, 50 mg/ml, 100 mg/ml  
Group C was treated with Doxycycline hyclate dissolved in Phosphate buffer solution 
at 4 different concentrations of 5 mg/ml, 20 mg/ml, 50 mg/ml,100 mg/ml.  
All the groups were further divided into two groups I, II based on treatment with 
collagenase enzyme where  
Group I – treated with collagenase 
Group II – treated without collagenase 
These samples were observed for changes of free protein content in the medium using 
spectrophotometer at optical density @ 595 nm at 4 different incubation periods i.e. 2, 
4, 7 and 14 days. These samples were also observed in the optical light microscope 
for the changes in surface topography of collagen membrane degradation and 
structural organization of collagen fibers on 2, 4, 7 and 14 days. 
Table 1,2,3,4,5,6  shows the master chart for free protein content in Group A,B, C 
treated with collagenase enzyme (Group I) and Group A,B, C treated without 
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collagenase enzyme (Group II) consists of  different values of protein content in 
medium on Day 2, 4, 7 & 14. 
Table 7, 8 & Figure 1 shows mean values of free protein content in Group A treated 
with and without collagenase respectively on Day 2, 4, 7 & 14. Results shows that 
Group A treated with collagenase has more protein release than Group A treated 
without collagenase and new protein release increases till Day 7 and then start 
decreasing upto Day 14 for Group A treated with collagenase. 
Table 9, 10 & Figure 2 shows mean values of  free protein content of  each of four 
different concentrations respectively in Group B treated with collagenase on Day 2, 4, 
7 & 14. Results shows at 5 mg/ml concentration of Group B I, new protein release 
increases steadily till day 14 while at 20 mg/ml, it decreases at day 4 and then 
increased till day 14. At 50 mg/ml, it was decreased at day 4 and then again increases 
and finally decreased to lowest new protein release at Day 14 compared to other three 
concentrations including 100 mg/ml which has maximum protein release at day 14 
although less protein release on Day 2 and 4 whereas mean values of free protein 
content of each of four different concentrations respectively in Group B treated 
without collagenase (B II) on Day 2, 4, 7 & 14 shows that at 5 mg/ml concentration, 
less new protein release in the beginning which increased till day 4 and again 
decreased to day 7 but the levels were more at Day 14. At 20 mg/ml, new protein 
release increased steadily upto day 7 and then decreased at day 14. At 50mg/ml, there 
was not much difference in new protein release at different days while at 100 mg/ml, 
the new protein release increased steadily upto day 14. 
From the mean values it was found that after Day 2 incubation, collagen membrane 
immersed in Group B I at 5 mg/ml solution exhibited 45 % less protein release into 
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the medium (less membrane degradation) while which immersed in 20mg/ml, 50 
mg/ml and 100 mg/ml exhibited 50%, 30% and 39% less membrane degradation 
respectively when compared with group A I. On day 4, Group B I at 5 mg/ml solution 
exhibited 38 % less protein release into the medium while which immersed in 
20mg/ml, 50 mg/ml and 100 mg/ml exhibited 60%, 55% and 60% less membrane 
degradation respectively when compared with group A I. On day 7, Group B I at 5 
mg/ml solution exhibited 48 % less protein release into the medium compared to 
group A I while which immersed in 20mg/ml, 50 mg/ml and 100 mg/ml exhibited 
33%, 53% and 37% less membrane degradation respectively when compared with 
group A I. On day 14, Group B I at 5mg/ml, 20mg/ml and 100 mg/ml solution 
exhibited 9 % , 14%, 21 % more protein release into the medium compared to group 
A I while which immersed in 50 mg/ml exhibited 42 % less membrane degradation 
when compared with group A I. 
Table 11, 12 & figure 3 shows mean values of  free protein content of each of four 
different concentrations respectively in Group C treated with collagenase ( C I ) on 
Day 2, 4, 7 & 14. Results shows that at 5 mg/ml concentration, less new protein 
release in the beginning which increased till day 4 but decreased steadily up to day 14. 
At 20 mg/ml, new protein release increased steadily upto day 7 and then decreased at 
day 14. At 50mg/ml, there was not much difference in new protein release at day 4 & 
day 7 but new protein release decreased at day 14 whereas at 100 mg/ml, the new 
protein release increased steadily upto day 17 and then decreased at day 14 whereas 
mean values of free protein content of each of four different concentrations 
respectively in Group C treated without collagenase (C II) on Day 2, 4, 7 & 14 shows 
that at 5 mg/ml concentration, less new protein release in the beginning which 
increased till day 4 but decreased up to day 14. At 20 mg/ml, new protein release 
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increased steadily up to day 14. At 50mg/ml, there was steady increase in new protein 
up to day 14 while at 100 mg/ml, the new protein release increased at day 4 and then 
decreased to day 14. 
In Group C I on Day 2, collagen membrane immersed at 5 mg/ml solution exhibited 
73 % less protein release into the medium while which immersed in 20mg/ml, 50 
mg/ml and 100 mg/ml exhibited 85%, 58% and 49% less membrane degradation 
respectively when compared with group A I. On day 4, Group C I at 5 mg/ml solution 
exhibited just 14 % less protein release into the medium while which immersed in 
20mg/ml, 50 mg/ml and 100 mg/ml exhibited 60%, 60% and 45% less membrane 
degradation respectively when compared with group A I. On day 7, Group C I at 5 
mg/ml solution exhibited 58 % less protein release into the medium compared to 
group A I while which immersed in 20mg/ml, 50 mg/ml and 100 mg/ml exhibited 
66%, 70% and 60% less membrane degradation respectively when compared with 
group A I. On day 14, Group B I at 5mg/ml and 20mg/ml exhibited 80%, 89% less 
protein released into the medium compared to group A I while which immersed in 50 
mg/ml and 100 mg/ml exhibited 75 % and 59 % less protein released when compared 
with group A I. 
Table 13 shows the comparison between group B and group A in both with and 
without collagenase groups and also comparison between group C and group A in 
both with and without collagenase groups through One way ANOVA. The P values 
were 0.000 (< 0.001) for all the comparisons between group A I and BI and also 
between A II and B II except on day 4 and day 7 where P values are 0.006 (< 0.01) 
i.e. significant. The P values were 0.000 (< 0.001) for all the comparisons between 
group A I and C I except on day 4 where P value was not significant and also 
significant between A II and C II except on day 2 where P values are not significant. 
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Table 14 shows the results of multiple comparison test (Tukey HSD post hoc test) for 
free protein content for group A I and B I. The results shows that P values between 
different concentration of tetracycline compared with control group were statistically 
significant (P < 0.001) but P values for comparisons between different concentration 
of tetracycline group treated with collagenase were not significant. 
Table 15 shows the results of multiple comparison test (Tukey HSD post hoc test) for 
free protein content for group A I and C I. The results shows that P values between 
different concentration of doxycyline compared with control group were statistically 
significant (P < 0.001) but P values for comparisons between different concentration 
of doxycyline group treated with collagenase were not significant. 
Table 16  shows the results of independent T test for comparison between mean 
values of free protein content of group A I ( control group with collagenase) and 
group A II (control group with collagenase) on different incubation periods. The 
results shows P values 0.000 (< 0.001) which is statistically significant. 
Table 17 shows the results of independent T test for comparison between mean 
values of free protein content of group B I ( tetracycline group with collagenase) and 
group B II (tetracycline group without collagenase)  at varying concentrations on 
different incubation periods. The results shows P values (< 0.01) were statistically 
significant at 5 mg/ml on day 2,4 and 7 while on day 14 P values were not significant. 
At 20 mg/ml only on day 14, P values are statistically significant. At 50 mg/ml, P 
values (< 0.001) were statistically significant on all the days. At 100 mg/ml, P values 
(< 0.01) were statistically significant. 
Table 18 shows the results of independent T test for comparison between mean 
values of free protein content of group C I ( doxycyline group with collagenase) and 
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group B II (doxycyline group without collagenase)  at varying concentrations on 
different incubation periods. The results shows P values (< 0.05) were statistically 
significant at 5 mg/ml on day 2,4 and 7 while on day 14 P values were not significant. 
At 20 mg/ml, P values (< 0.05) were statistically significant. At 50 mg/ml, P values (< 
0.01) were statistically significant on day 2 and 14 but the values are not significant 
on day 4,7. At 100 mg/ml, P values (< 0.05) were statistically significant on day 2 
while P values (< 0.01) were statistically significant on day 4 and 7 but not significant 
on day 14. 
Photomicrograph 1,2,3,4 shows microscopic view of remaining collagen membrane 
in medium containing Phosphate buffer solution treated with collagenase (group A I). 
Loss of collagen structure was observed from day 2 which continue up to day 14 
when it was observed as almost complete loss of collagen membrane leaving behind 
few collagen fibers. 
Photomicrograph 5 shows microscopic view of remaining collagen membrane in 
medium containing group B I at 5 mg/ml concentration over different incubation 
periods. On day 2 the collagen membrane was appeared to be structurally 
disorganized which continue to loss the structure over the time up to day 14 when 
small collagen fibers were left in the medium. 
Photomicrograph 6 shows microscopic view of remaining collagen membrane in 
medium containing group B I at 20 mg/ml concentration over different incubation 
periods. Destruction of collagen fibers were observed from day 2 which continue to 
increased up to day 14 where disorganized collagen fibers were seen. 
Photomicrograph 7 shows microscopic view of remaining collagen membrane in 
medium containing group B I at 50 mg/ml concentration over different incubation 
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periods. No change in collagen structure were observed on day 2 and day 4 but the 
degeneration collagen fibers were first observed on day 7 with not much increased 
loss of collagen on day 14. 
Photomicrograph 8 shows microscopic view of remaining collagen membrane in 
medium containing group B I at 100 mg/ml concentration over different incubation 
periods. Destruction of collagen fibers were observed from day 7 which was found to 
be maximum on day 14  
Photomicrograph 9 shows microscopic view of remaining collagen membrane in 
medium containing group C I at 5 mg/ml concentration over different incubation 
periods. No change in the structure of collagen membrane was found upto day 4. It 
was first appeared to be structurally disorganized on day 7which continue to loss the 
structure over the time up to day 14  
Photomicrograph 10 shows microscopic view of remaining collagen membrane in 
medium containing group C I at 20 mg/ml concentration over different incubation 
periods. No change in the structure of collagen membrane was observed  up to day 14.  
Photomicrograph 11 shows microscopic view of remaining collagen membrane in 
medium containing group C I at 50 mg/ml concentration over different incubation 
periods. No change in collagen structure were observed on day 2 but the disorganized 
collagen fibers were first observed on day 4 which was seen slightly more  on day 14. 
Photomicrograph 12 shows microscopic view of remaining collagen membrane in 
medium containing group C I at 100 mg/ml concentration over different incubation 
periods. Destruction of collagen fibers were observed from day 7 which was found to 
be more on day 14. 
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Table 1: 
Free Protein content in Group A-I 
MASTER CHART  
S.No  Day 2  Day 4 Day 7 Day 14 
1 0.211 0.246 0.399 0.284 
2 0.285 0.313 0.364 0.291 
3 0.301 0.351 0.482 0.234 
4 0.199 0.212 0.298 0.213 
5 0.264 0.29 0.406 0.25 
6 0.324 0.328 0.461 0.228 
 
 
Table 2: 
Free Protein content in Group A -II 
MASTER CHART  
S.No. Day 2  Day 4 Day 7 Day 14 
1 0.016 0.056 0.122 0.158 
2 0.011 0.042 0.137 0.162 
3 0.031 0.068 0.169 0.235 
4 0.024 0.071 0.151 0.193 
5 0.029 0.089 0.179 0.201 
6 0.032 0.100 0.148 0.209 
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Table 3: 
Free Protein content in Group B- I 
MASTER CHART  
CONCENTRATION Day 2  Day 4 Day 7 Day 14 
5mg/ml  0.145 0.153 0.209 0.273  
0.134 0.14 0.158 0.219 
0.151 0.166 0.192 0.208 
0.158 0.161 0.248 0.312 
0.131 0.144 0.212 0.341 
0.154 0.158 0.236 0.288 
20mg/ml 0.138 0.118 0.322 0.348 
0.152 0.126 0.298 0.375 
0.145 0.122 0.269 0.304 
0.132 0.113 0.23 0.286 
0.115 0.094 0.175 0.256 
0.113 0.109 0.089 0.151 
50mg/ml 0.128 0.166 0.166 0.258 
0.122 0.112 0.136 0.104 
0.184 0.132 0.19 0.145 
0.212 0.128 0.202 0.132 
0.232 0.136 0.212 0.124 
0.226 0.122 0.231 0.107 
100mg/ml 0.123 0.100 0.321 0.328 
0.117 0.095 0.155 0.205 
0.105 0.050 0.213 0.299 
0.162 0.115 0.255 0.304 
0.242 0.105 0.299 0.256 
0.223 0.225 0.287 0.432 
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Table 4: 
Free Protein content in Group B- II 
MASTER CHART  
 
CONCENTRATION Day 2  Day 4 Day 7 Day 14 
5mg/ml 0.01 0.081 0.039 0.058 
0.006 0.06 0.042 0.112 
0.014 0.075 0.053 0.094 
0.024 0.079 0.075 0.108 
0.012 0.075 0.038 0.119 
0.018 0.08 0.071 0.073 
20mg/ml 0.024 0.079 0.156 0.165 
0.032 0.062 0.181 0.128 
0.021 0.052 0.142 0.142 
0.016 0.078 0.199 0.114 
0.054 0.042 0.203 0.114 
0.045 0.058 0.205 0.105 
50mg/ml 0.025 0.052 0.054 0.037 
0.032 0.066 0.043 0.051 
0.081 0.075 0.032 0.053 
0.051 0.061 0.051 0.042 
0.047 0.072 0.035 0.065 
0.046 0.070 0.043 0.058 
100mg/ml 0.036 0.053 0.141 0.201 
0.047 0.051 0.115 0.186 
0.029 0.065 0.128 0.178 
0.021 0.037 0.156 0.217 
0.037 0.058 0.155 0.191 
0.012 0.042 0.151 0.233 
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Table 5: 
Free Protein content in Group C- I 
MASTER CHART  
 
 
 
 
 
 
 
CONCENTRATION Day 2  Day 4 Day 7 Day 14 
5mg/ml 0.1 0.074 0.094 0.16 
0.102 0.122 0.159 0.023 
0.072 0.103 0.168 0.05 
0.042 0.086 0.184 0.032 
0.053 0.136 0.212 0.019 
0.064 0.98 192 0.016 
20mg/ml 0.078 0.121 0.161 0.022 
0.038 0.112 0.135 0.029 
0.064 0.079 0.031 0.088 
0.022 0.152 0.212 0.013 
0.018 0.116 0.193 0.016 
0.015 0.092 0.078 0.006 
50mg/ml 0.1 0.077 0.129 0.049 
0.101 0.089 0.038 0.157 
0.042 0.158 0.128 0.025 
0.062 0.104 0.118 0.064 
0.037 0.134 0.152 0.053 
0.031 0.062 0.143 0.036 
100mg/ml 0.155 0.213 0.199 0.076 
0.076 0.151 0.162 0.103 
0.025 0.124 0.126 0.053 
0.145 0.171 0.174 0.243 
0.041 0.151 0.165 0.107 
0.014 0.151 0.146 0.036 
_____________________________________________________________________________Results 
47 
 
 
 
Table 6: 
Free Protein content in Group C-II 
MASTER TABLE 
 
 
 
 
 
 
 
 
CONCENTRATION Day 2  Day 4 Day 7 Day 14 
5mg/ml 0.026 0.201 0.1 0.062 
0.013 0.116 0.151 0.093 
0.02 0.144 0.118 0.1 
0.031 0.132 0.122 0.128 
0.011 0.141 0.123 0.141 
0.019 0.13 0.094 0.076 
20mg/ml 0.013 0.011 0.050 0.059 
0.008 0.014 0.030 0.070 
0.019 0.023 0.041 0.062 
0.035 0.030 0.039 0.051 
0.015 0.025 0.052 0.074 
0.024 0.035 0.034 0.056 
50mg/ml 0.009 0.038 0.067 0.128 
0.014 0.069 0.093 0.152 
0.011 0.049 0.076 0.133 
0.016 0.101 0.123 0.197 
0.015 0.073 0.107 0.121 
0.019 0.084 0.092 0.181 
100mg/ml 0.009 0.094 0.076 0.054 
0.015 0.114 0.1 0.081 
0.011 0.109 0.09 0.061 
0.021 0.138 0.112 0.099 
0.013 0.1 0.084 0.078 
0.021 0.129 0.138 0.113 
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Table 7: 
MEAN VALUES OF FREE PROTEIN CONTENT in GROUP A- I 
 
Incubation period Number of 
samples 
Mean  Standard 
deviation 
Day 2  6 0.264 0.049 
Day 4 6 0.290 0.052 
Day 7 6 0.401 0.066 
Day 14 6 0.250 0.031 
 
 
 
 
 
 
Table 8: 
MEAN VALUES OF FREE PROTEIN CONTENT IN GROUP A- II 
 
Incubation period Number of 
samples 
Mean  Standard 
deviation 
Day 2  6 0.023 0.008 
Day 4 6 0.071 0.021 
Day 7 6 0.151 0.020 
Day 14 6 0.193 0.029 
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Table 9: 
MEAN VALUES OF FREE PROTEIN CONTENT in GROUP B-I     
 
Concentration Incubation 
period 
Number of 
samples 
Mean  Standard 
deviation 
5mg/ml Day 2  6 0.145 0.010 
Day 4 6 0.153 0.010 
Day 7 6 0.209 0.032 
Day 14 6 0.273 0.051 
20 mg/ml Day 2  6 0.132 0.015 
Day 4 6 0.113 0.011 
Day 7 6 0.230 0.086 
Day 14 6 0.286 0.079 
50 mg/ml Day 2  6 0.184 0.048 
Day 4 6 0.132 0.018 
Day 7 6 0.189 0.034 
Day 14 6 0.145 0.057 
100mg/ml Day 2  6 0.162 0.058 
Day 4 6 0.115 0.058 
Day 7 6 0.255 0.061 
Day 14 6 0.304 0.074 
 
Table 10: 
MEAN VALUES OF FREE PROTEIN CONTENT in GROUP B-II                        
Concentration Incubation 
period 
Number of 
samples 
Mean  Standard 
deviation 
5mg/ml Day 2  6 0.014 0.006 
Day 4 6 0.075 0.007 
Day 7 6 0.053 0.016 
Day 14 6 0.094 0.024 
20mg/ml Day 2  6 0.032 0.014 
Day 4 6 0.061 0.014 
Day 7 6 0.181 0.026 
Day 14 6 0.128 0.022 
50g/ml Day 2  6 0.047 0.019 
Day 4 6 0.066 0.026 
Day 7 6 0.043 0.036 
Day 14 6 0.051 0.036 
100mg/ml Day 2  6 0.030 0.009 
Day 4 6 0.051 0.022 
Day 7 6 0.141 0.039 
Day 14 6 0.201 0.051 
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Table 11: 
MEAN VALUES OF FREE PROTEIN CONTENT in GROUP C –I  
Concentration Incubation 
period 
Number of 
samples 
Mean  Standard 
deviation 
5mg/ml Day 2  6 0.072 0.024 
Day 4 6 0.250 0.358 
Day 7 6 0.168 0.040 
Day 14 6 0.050 0.055 
20mg/ml Day 2  6 0.039 0.026 
Day 4 6 0.112 0.025 
Day 7 6 0.135 0.069 
Day 14 6 0.029 0.029 
50mg/ml Day 2  6 0.062 0.031 
Day 4 6 0.114 0.036 
Day 7 6 0.118 0.040 
Day 14 6 0.064 0.047 
100mg/ml Day 2  6 0.076 0.061 
Day 4 6 0.160 0.029 
Day 7 6 0.162 0.024 
Day 14 6 0.103 0.073 
 
Table 12: 
MEAN VALUES OF FREE PROTEIN CONTENT in GROUP C-II  
concentration Incubation 
period 
Number of 
samples 
Mean  Standard 
deviation 
5mg/ml Day 2  6 0.020 0.007 
Day 4 6 0.144 0.029 
Day 7 6 0.118 0.020 
Day 14 6 0.100 0.030 
20mg/ml Day 2  6 0.019 0.009 
Day 4 6 0.023 0.009 
Day 7 6 0.041 0.008 
Day 14 6 0.062 0.008 
50mg/ml Day 2  6 0.014 0.003 
Day 4 6 0.069 0.022 
Day 7 6 0.093 0.020 
Day 14 6 0.152 0.030 
100mg/ml Day 2  6 0.015 0.050 
Day 4 6 0.114 0.016 
Day 7 6 0.100 0.022 
Day 14 6 0.081 0.022 
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Table 13: 
ONE WAY ANOVA FOR BETWEEN GROUP COMPARISONS  
 
 
 
 
 
 
 GROUP BETWEEN 
GROUPS 
SIGNIFICANCE 
Protein content 
at Day 2 
           A I               B I    0.000 
           B I 
Protein content 
at Day 4 
           A I               B I    0.000 
           B I 
Protein content 
at Day 7 
           A I               B I    0.000 
           B I 
Protein content 
at Day 14 
           A I               B I    0.001 
           B I 
Protein content 
at Day 2 
           A II               B II    0.006 
           B II 
Protein content 
at Day 4 
           A II               B II    0.007 
           B II 
Protein content 
at Day 7 
           A II               B II    0.000 
           B II 
Protein content 
at Day 14 
           A II               B II    0.000 
           B II 
Protein content 
at Day 2 
           A I               C I    0.000 
           C I 
Protein content 
at Day 4 
           A I               C I    0.192 
           C I 
Protein content 
at Day 7 
           A I               C I    0.000 
           C I 
Protein content 
at Day 14 
           A I               C I    0.000 
           C I 
Protein content 
at Day 2 
           A II               C II    0.156 
           C II 
Protein content 
at Day 4 
           A II               C II   0.000 
           C II 
Protein content 
at Day 7 
           A II               C II   0.000 
           C II 
Protein content 
at Day 14 
           A II               C II   0.000 
           C II 
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Table 14: 
MULTIPLE COMPARISON POST HOC TESTS 
PROTEIN CONTENT IN MEDIUM FOR GROUP B I & A I 
                                 5 mg/ml        20 mg/ml           50 mg/ml         100mg/ml        A I         
                 ***                                                           *** 
Day 2                       0.145                   0.132                       0.184               0.162   **     0.264            
                                                                                                       * 
                          ***                                                    
Day 4                       0.153                    0.113      ***          0.132              0.115 ***      0.290 
                                                                                                    *** 
                             ***  
Day 7                      0.209                     0.230     ***             0.189             0.255 **          0.401 
                                                                                                    *** 
 
D ay 14                   0.273                     0.286                         0.145            0.304               0.250 
                                                                                                                        * 
 
 
 
 
The results are presented as mean ± standard deviation 
P < 0.05 *, P < 0.01 **, P < 0.001 *** 
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Table 15: 
MULTIPLE COMPARISON POST HOC TESTS 
PROTEIN CONTENT IN MEDIUM FOR GROUP C I & A I 
                                 5 mg/ml        20 mg/ml           50 mg/ml         100mg/ml        A I         
                 ***                                                           *** 
Day 2                       0.072                   0.039                       0.062               0.076 ***     0.264            
                                                                                                       *** 
                                                                              
Day 4                       0.250                    0.112                     0.114              0.160             0.290 
                                                                                                     
                             ***  
Day 7                      0.168                     0.135     ***             0.118            0.162 ***          0.401 
                                                                                                    *** 
                               *** 
D ay 14                   0.050                    0.029                         0.064           0.103***           0.250 
                                                                                                                         *** 
 
 
 
The results are presented as mean ± standard deviation 
P < 0.05 *, P < 0.01 **, P < 0.001 *** 
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Table 16:  
INDEPENDENT T TEST - GROUP A I Vs A II 
 Incubation 
period 
Group Group No. of 
samples 
Significance 
 
 
 
BSA 
Day 2        A         I       6       0.000 
        II       6 
Day 4        A         I       6       0.000 
        II       6 
Day 7        A         I       6       0.000 
        II       6 
Day 14        A         I       6       0.000 
        II       6 
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Table 17:  
INDEPENDENT T TEST – Group B I Vs B II 
Concentration Incubation 
period 
Group Group No. of 
samples 
Significance 
 
 
 
5 mg/ml 
Day 2        B         I       6       0.001 
        II       6 
Day 4        B         I       6       0.048 
        II       6 
Day 7        B         I       6       0.022 
        II       6 
Day 14        B         I       6       0.080 
        II       6 
 
   
 
20 mg/ml 
 
 
 
Day 2        B 
 
        I       6       0.108 
        II       6 
Day 4        B         I       6       0.223 
        II       6 
Day 7        B         I       6       0.263 
        II       6 
Day 14        B         I       6       0.000 
        II       6 
  
 
 
50 mg/ml 
 
Day 2        B         I       6       0.000 
        II       6 
Day 4        B         I       6       0.000 
        II       6 
Day 7        B         I       6       0.000 
        II       6 
Day 14        B         I       6       0.003 
        II       6 
 
 
100mg/ml 
Day 2        B         I       6       0.000 
        II       6 
Day 4        B         I       6       0.025 
        II       6 
Day 7        B         I       6       0.001 
        II       6 
Day 14        B         I       6       0.010 
        II       6 
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Table 18:  
INDEPENDENT T TEST – Group C I vs C II 
 
Concentration Incubation 
period 
Group Group No. of 
samples 
Significance 
 
 
 
5 mg/ml 
Day 2        C         I       6       0.001 
        II       6 
Day 4        C         I       6       0.048 
        II       6 
Day 7        C         I       6       0.022 
        II       6 
Day 14        C         I       6       0.080 
        II       6 
 
   
 
20 g/ml 
 
 
 
Day 2        C 
 
        I       6       0.01 
        II       6 
Day 4        C         I       6       0.02 
        II       6 
Day 7        C         I       6       0.02 
        II       6 
Day 14        C         I       6       0.01 
        II       6 
  
 
 
50 mg/ml 
 
Day 2        C         I       6       0.004 
        II       6 
Day 4        C         I       6       0.073 
        II       6 
Day 7        C         I       6       0.210 
        II       6 
Day 14        C         I       6       0.003 
        II       6 
 
 
100mg/ml 
Day 2        C         I       6       0.035 
        II       6 
Day 4        C         I       6       0.008 
        II       6 
Day 7        C         I       6       0.001 
        II       6 
Day 14        C         I       6       0.501 
        II       6 
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Table 19:  
Independent T test: Comparison between group B 50 mg/ml and group C 20 
mg/ml with collagenase 
 
 Incubation 
period 
Group Group No. of 
samples 
Significance 
 
 
 
Free Protein 
content in 
the medium 
Day 2 B 50 
mg/ml 
        I 
         
      6       0.000 
C 20 
mg/ml 
      6 
Day 4 B 50 
mg/ml 
        I 
         
      6       0.115 
C 20 
mg/ml 
      6 
Day 7 B 50 
mg/ml   
        I 
         
      6       0.136 
C 20 
mg/ml 
      6 
Day 14 B 50 
mg/ml     
        I 
        
      6       0.001 
C 20 
mg/ml 
      6 
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Figure 1: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group A I and A II  
 
 
Figure 2: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group B I and B II  
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Figure 3: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group C I and C II  
 
 
Figure 4: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group A I and B I  
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Figure 5: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group A I and C I 
 
 
Figure 6: Comparison of mean values of free protein content in 
medium (optical density @ 595nm) between group B I and C I  
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PHOTOMICROGRAPH 1: GROUP A- I 100 X MAGNIFICATION (DAY 2) 
 
                          
 
  
 
   
 
 
 
PHOTOMICROGRAPH 2: GROUP A – I 40 X MAGNIFICATION (DAY 4) 
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PHOTOMICROGRAPH 3: GROUP A- I 40 X MAGNIFICATION (DAY7)   
        
     
 
 
 
 
 
 
PHOTOMICROGRAPH 4: GROUP A- I 100 X MAGNIFICATION (DAY 14)                       
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PHOTOMICROGRAPH 5: GROUPB- I  (5mg/ml) 
 
       
   (i) 100 X Magnification (Day 2)                                 (ii) 40 X Magnification (Day 4) 
                                                                                                    
               
  (iii)  100 X Magnification (Day 7)                                (iv) 40 X Magnification (Day 14) 
 
PHOTOMICROGRAPH 6 : GROUP B – I   (20mg/ml) 
 
       
  (i) 100 X Magnification  (Day 2)                                 (ii) 100 X Magnification (Day 4) 
  
                                        
(iii) 100 X Magnification  (Day 7)                               (iv) 100 X Magnification (Day 14) 
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   PHOTOMICROGRAPH 7: GROUP B – I   (50mg/ml) 
 
       
(i) 100 X Magnification (Day 2)                                   (ii) 100 X Magnification (Day 4) 
 
      
(iii) 100 X Magnification (Day 7)                                 (iv) 100 X Magnification (Day 14) 
 
                                                                                                                                                                         
PHOTOMICROGRAPH 8: GROUP B –I (100mg/ml) 
 
        
(i) 100 X Magnification (Day 2)                                    (ii) 100 X Magnification (Day 4) 
        
(iii) 100 X Magnification  (Day 7)                                  (iv) 100 X Magnification (Day 14) 
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PHOTOMICROGRAPH 9: GROUP C- I (5mg/ml) 
 
       
(i) 100 X Magnification (Day 2)                                     (ii) 100 X Magnification (Day 4) 
 
       
 (iii) 100 X Magnification (Day 7)                                  (iv) 100 X Magnification (Day 14) 
 
PHOTOMICROGRAPH 10: GROUP C – I (20mg/ml) 
 
       
(i) 100 X Magnification (Day 2)                                     (ii) 100 X Magnification (Day 4) 
 
       
(iii) 100 X Magnification (Day 7)                                  (iv) 100 X Magnification (Day 14) 
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PHOTOMICROGRAPH 11: GROUP C- I (50mg/ml) 
 
       
(i) 100 X Magnification (Day 2)                                     (ii) 100 X Magnification (Day 4) 
 
         
(iii) 100 X Magnification (Day 7                                     (iv) 100 X Magnification (Day 14) 
 
PHOTOMICROGRAPH 12: GROUP C- I (100mg/ml) 
 
      
(i) 100 X Magnification (Day 2)                                    (ii) 100 X Magnification (Day 4) 
 
       
(iii) 100 X Magnification (Day 7)                                  (iv) 100 X Magnification (Day 14) 
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                                                      DISCUSSION 
 
Collagen comprises the most substantial group of structural proteins in connective 
tissue and it represents about one third of total body proteins. The rationale behind 
using collagen as a barrier is, as it is an extracellular macromolecule for periodontal 
connective tissue and is physiologically metabolized; it is chemotactic for fibroblasts, 
hemostatic and a weak immunogen and scaffolding for migrating cells.  
Collagenase is thought to play a major role in the enzymatic degradation of 
collagenous materials. If the collagen membranes are prematurely resorbed, their 
barrier effect may be significantly reduced
26,67
. As the structural integrity of the 
collagen membrane for a sufficient period of time is essential for the success of 
guided tissue regeneration procedure, degradation time of bioresorbable collagen 
membranes should be prolonged to get better results. 
Various materials have been used to control the rate of bioresorbable collagen 
membranes degradation. Tetracycline and its semisynthetic analogue doxycycline are 
the compounds which possess antibacterial and anticollagenolytic properties
51
. So 
tetracycline prolongs collagen membrane degradation by a local effect on tissue and 
anticollagenolytic effect 
Ofer Moses et al 
53 
recently proved that collagen membranes immersed in TTC 
solution prior to their implantation and systemic administration of TTC significantly 
decreased the membranes degradation.
 
Also Ofer Moses et al
54  
proved that collagen 
membranes immersed in 50 mg/ml tetracycline hydrochloride solution exhibited the 
longest degradation time, both in clostridial collagenase and human bone lineage cell 
assays in vitro.
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In the present study, we analyzed the effects of bioresorbable collagen membranes on 
their rate of degradation by clostridial collagenase when immersed in varying 
concentration of tetracycline and doxycycline in vitro by spectrophotometric analysis 
(quantitatively) and optical microscopic analysis (qualitatively). 
Our findings showed that both tetracycline and doxycycline delays the degradation of 
collagen membranes differently at varying concentrations. 
Quantitative analysis revealed that protein release in the medium analyzed by 
spectrophotometer at optical density @ 595nm was less at higher concentration of 
tetracycline while it was less at lower concentration of doxycycline. 
This may indicate that more collagen degradation was observed in solution containing 
lower concentration of tetracycline whereas more collagen degradation was observed 
in solution containing higher concentrations of doxycycline. Also it was found that 
tetracycline at 50 mg/ml was most effective in delaying collagen membrane 
degradation in clostridial collagenase which is in accordance with the study by Ofer 
Moses
54 
which proved that collagen membranes immersed in 50 mg/ml tetracycline 
hydrochloride solution exhibited the longest degradation time, both in clostridial 
collagenase and human bone lineage cell assays in vitro.
  
In doxycycline, 20mg/ml concentration was found to be more effective in delaying 
collagen membrane degradation as the new protein release into the medium was less 
up to day 14 as compared with the group without collagenase both quantitatively and 
qualitatively. 
Quantitative analysis also showed that 100 mg/ml concentration of tetracycline found 
to exhibit higher new protein release into the medium after day 7 up to day 14. The 
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reason for the above is low pH which was created by this concentration led to faster 
collagen degradation compared to group without collagenase.  
It is also evident from this study that the semisynthetic tetracyclines, doxycycline are 
more effective inhibitors of collagenase than the parent compound, tetracycline HCl. 
This concides with the clinical study which suggested that the administration of 
doxycycline to humans with periodontal disease appeared to inhibit collagenase 
enzyme in the periodontal pocket for a longer period of time than tetracycline
9
. The 
greater inhibitory activity of doxycycline is due to its ability to bind Zn2+ more 
tightly than the other tetracyclines.  
On comparing the mean values of free protein content of group B I with group B II, 
the results of the present study shows that statistically significant difference (P < 0.01) 
were found at each concentration of tetracycline over day 2, 4, 7 & 14 except in 20 
mg/ml concentration,  statistically significant difference (P < 0.0001) was found only 
on day 14.  
Qualitative analysis using light optical microscope for group B I shows that 
disorganization and destruction of collagen fibers at tetracycline concentration of 5 
mg/ml & 20 mg/ml were first observed on day 2 which steadily increases up to day 14 
while disorganization of collagen fibers at tetracycline concentration 50 mg/ml & 100 
mg/ml were first observed on day 7 whereas maximum disorganization of collagen 
fibers at 100 mg/ml was observed on day 14 as compared to 50 mg/ml. So in the 
present study quantitative and qualitative proved that tetracycline is more effective at 
50 mg/ml concentration which is in agreement with Ofer Moses
57  
study which proved 
that collagen membranes immersed in 50 mg/ml tetracycline hydrochloride solution 
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exhibited the longest degradation time, both in clostridial collagenase and human 
bone lineage cell assays in vitro.
  
On comparing the mean percentage of group C I with group C II, the results of the 
present study shows that statistically significant difference (P < 0.05) were found at 5 
mg/ml & 20 mg/ml concentration of doxycycline  over day 2, 4, 7 & 14 while  50 
mg/ml  & 100 mg/ml concentration where all the values were not significant. This 
might suggest that doxycycline 5 mg/ml and 20 mg/ml are more effective in 
prolonging the collagen membrane degradation time by effectively inhibiting 
clostridial collagenase. 
Qualitative analysis for group C I shows that disorganization and destruction of 
collagen fibers for doxycycline were first observed on day 4 for 50 & 100 mg/ml 
concentration which steadily increases up to day 14 while disorganization of collagen 
fibers at doxycycline concentration 5 mg/ml were first observed on day 7 whereas at 
20 mg/ml, it was first observed on day 14. So 20 mg/ml was found to be most 
effective in delaying collagen membrane degradation qualitatively also. So in the 
present study quantitative and qualitative analysis led to conclusion that doxycycline 
is more effective at 20 mg/ml concentration.  
So combining quantititave and qualitative results, 50 mg/ml concentration of 
tetracycline and 20 mg/ml concentration of doxycycline were found to be most 
effective in delaying collagen degradation in vitro compared to their respective groups 
without collagenase.  
On comparing the most effective concentration of tetracycline hydrochloride with 
most effective concentration of doxycycline hyclate, statistically significant difference 
was found  on day 2 (P< 0.0001) and day 14 which showed doxycyline was more 
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effective in inhibiting clostridial collagenase enzyme than tetracycline group which is 
in line with the clinical study which suggested that the administration of doxycycline 
to humans with periodontal disease appeared to inhibit collagenase enzyme in the 
periodontal pocket for a longer period of time than tetracycline. So another significant 
finding of this study was that doxycycline was found to be more effective in delaying 
collagen membrane degradation than tetracycline when treated with clostridial 
collagenase in vitro.  
Since tetracycline and doxycyline have anti-inflammatory and anticollagenolytic 
action when immersed in barrier membrane it enhances the structural integrity of 
membrane thereby increasing the regenerative potential, further research is needed to 
observe the effects. 
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                                                 SUMMARY AND CONCLUSION 
 
In the present study, our aim was to evaluate the effects of varying concentration of 
tetracycline and doxycycline on the rate of degradation of bioresorbable collagen 
membranes by clostridial collagenase when immersed in vitro using 
spectrophotometric  and microscopic analysis. 
The present study showed that: 
 Both tetracycline and doxycycline modulates the degradation of collagen 
membranes differently at varying concentrations. 
 Free protein release in the medium was less at higher concentration of 
tetracycline hydrochloride while it was less at lower concentration of 
doxycycline. 
 Tetracycline at 50 mg/ml concentration was most effective in delaying 
collagen membrane degradation in clostridial collagenase  
 Doxycycline at 20mg/ml concentration was found to be most effective in 
delaying collagen membrane degradation in clostridial collagenase both 
quantitatively and qualitatively. 
 Doxycycline is more effective in delaying collagen membrane degradation in 
clostridial collagenase than tetracycline or when no drug is present. 
 
This confirms that tetracycline at 50 mg/ml concentration and doxycycline at 20 
mg/ml concentration are effective in delaying collagen membrane degradation in 
clostridial collagenase in vitro. Moreover further research is needed to see the effects 
of doxycycline on rate of collagen membrane degradation in vivo. 
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